BioLineRX (BLRX) Stock: Buy, Sell, or Hold?
BLRX - BioLineRX Ltd
$2.37
0.02 (0.85%)
▲
5d:
-8.85%
30d:
-13.5%
90d:
-24.93%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 23, 2026
Get Alerted When BLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BLRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BLRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BLRX is currently trading at $2.37, which is considered oversold relative to its 30-day fair value range of $2.42 to $2.70.
Technical Outlook: Technically, BLRX is in a strong downtrend. The price is currently testing key support at $2.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BLRX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.00 (+828.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BLRX is in a strong downtrend. The price is currently testing key support at $2.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BLRX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.00 (+828.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.42 -
$2.70
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 828.3% below Wall St target ($22.00)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.42 -
$2.70
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.30
Resistance Level
$2.60
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.94
Wall Street Target
$22.00
(+828.3%)
Revenue Growth (YoY)
-3.3%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
